Magenta Therapeutics, Inc is a clinical-stage biotechnology company. The Company is developing medicines to bring the curative power of immune reset to more patients with autoimmune diseases, blood cancers and genetic diseases. The Company developing an integrated platform to change the treatment landscape in both autologous and allogeneic transplant, and provide access to a one-time curative treatment option for more patients with autoimmune diseases, hematologic malignancies and genetic diseases. The Company is also developing a portfolio of biologics, including antibody drug conjugates, small molecules and a cell therapy. The Company’s products include MGTA-145, CD45-ADC, MGTA-456 and MGTA-117.